Table 2.
Independent Predictors of NOAC Use
| Characteristic | OR* | 95% CI | P-value |
|---|---|---|---|
| Age (vs. 75–79) | |||
| 80–84 | 0.675 | (0.536, 0.852) | 0.001 |
| 85–89 | 0.665 | (0.507, 0.873) | 0.003 |
| ≥ 90 | 0.390 | (0.254, 0.599) | <0.001 |
| Women (vs. men) | 1.335 | (1.090, 1.636) | 0.005 |
| White (vs. non-white) | 1.501 | (1.073, 2.099) | 0.018 |
| Median income (vs. 1st tertile) | |||
| 2nd tertile | 0.957 | (0.851, 1.354) | 0.74 |
| 3rd tertile | 1.257 | (0.737, 1.258) | 0.07 |
| Body mass index (vs. < 25) | |||
| 25 to < 30 | 1.074 | (0.851, 1.354) | 0.55 |
| ≥ 30 | 0.963 | (0.737, 1.258) | 0.78 |
| Hemoglobin (per 1 g/dl increase) | 1.196 | (1.132, 1.263) | <0.001 |
| Creatinine Clearance, ≥ 50 (vs. < 50) | 1.368 | (1.077, 1.736) | 0.010 |
| Medical service (vs. surgical service) | 1.260 | (0.737, 1.258) | 0.041 |
| Heart failure, yes (vs. no) | 1.097 | (1.132, 1.263) | 0.39 |
| Hypertension, yes (vs. no) | 1.323 | (0.851, 1.354) | 0.044 |
| Diabetes, yes (vs. no) | 0.795 | (1.077, 1.736) | 0.05 |
| Stroke/TIA yes (vs. no) | 1.573 | (1.062, 1.101) | 0.016 |
| Peripheral vascular disease, yes (vs. no) | 0.930 | (0.851, 1.354) | 0.61 |
| Coronary artery disease, yes (vs. no) | 0.872 | (0.737, 1.258) | 0.21 |
| Dementia, yes (vs. no) | 0.780 | (1.132, 1.263) | 0.15 |
| Gastrointestinal bleeding, yes (vs. no) | 0.746 | (1.077, 1.736) | 0.43 |
| Intracranial bleeding, yes (vs. no) | 0.386 | (1.062, 1.101) | 0.043 |
| Modified HAS-BLED score, ≥3 yes (vs. <3) | 0.744 | (1.132, 1.263) | 0.015 |
| Time point (per 1 quarter increase) | 1.081 | (1.062, 1.101) | <0.001 |
*
Adjusted odds ratio of being prescribed a NOAC
NOAC: new oral anticoagulant; TIA: transient ischemic attack. Modified HAS-BLED: hypertension, kidney disease, liver disease, stroke, bleeding history (bleeding or gastrointestinal bleeding or intracranial bleeding or lung/thoracic bleeding or soft tissue hematoma), elderly (age >65), drugs (aspirin or clopidogrel or prasugrel or ticagrelor), alcohol abuse.